Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Diagnostic methods and compositions for cancer immunotherapy

A cancer, chimeric antigen receptor technology, applied in the field of diagnosis and composition for cancer immunotherapy, which can solve problems such as difficulty in discovery and treatment

Pending Publication Date: 2021-08-13
F HOFFMANN LA ROCHE & CO AG
View PDF68 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In particular, malignant solid tumors metastasize and grow in an uncontrolled manner, which makes timely detection and treatment extremely difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic methods and compositions for cancer immunotherapy
  • Diagnostic methods and compositions for cancer immunotherapy
  • Diagnostic methods and compositions for cancer immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0813] Example 1. Correlation of T cell expansion patterns with different gene expression patterns in the tumor microenvironment and adjacent normal tissues

[0814]After T cells encounter their cognate antigen, clonal expansion can occur to generate multiple copies of the cell with a shared T cell receptor (TCR). Despite the fundamental role of clonal expansion in cancer immunity, little is known about the relationship between T cell subsets or antitumor responses in cancer patients. This example describes experiments to sequence TCR and RNA in single CD3+ T cells from primary non-small cell lung cancer and matched adjacent normal tissue (NAT). The data obtained from these studies indicated that, although the majority of clonotypes were represented by single cells, the remaining clonal lineages showed expansion only in NAT or tumor, or double-resident expansion in both compartments. Activated CD4+ T cells showed NAT expansion; resident memory T cells showed tumor expansion; ...

example 2

[0902] Example 2. Relationship Between Gene Expression Patterns and Responsiveness to PD-L1 Axis Binding Antagonist Therapy

[0903] In the TIL populations of the three patients analyzed in Example 1, the clonal residency pattern ( Figure 1D ) and T cell subsets were different. The different fractions of Tcyt, Tem and NKT cells in different patients were particularly obvious ( Figure 5A ). Therefore, it was explored whether gene expression patterns in the TIL population could correlate with clinical response to PD-L1 axis-binding antagonist therapy, such as atezolizumab. To this end, Gene Set Enrichment Analysis (GSEA) (Subramanian, A. et al. Proc Natl AcadSci USA 102, 15445–15550, 2005; and Lamb, J. et al. Science 313, 1929-1935, 2006) was applied to Pretreatment tumor RNA-seq data from a randomized clinical trial (POPLAR, (Fehrenbacher, L. et al. Lancet 387, 1837–1846 (2016))) in 193 patients with NSCLC in which the anti-PD-L1 antibody atezolizumab was compared with Th...

example 3

[0942] Example 3. Determining a patient's propensity to respond to PD-L1 axis binding antagonist therapy and treating the patient accordingly

[0943] Using the compositions and methods described herein, the likelihood of a cancer patient responding to therapy with a PD-L1 axis binding antagonist can be determined. For example, suffering from a cancer described herein such as lung cancer (e.g., non-small cell lung cancer), bladder cancer (e.g., urothelial carcinoma), kidney cancer (e.g., renal cell carcinoma), or breast cancer (e.g., triple-negative breast cancer) ) patients can receive one or more gene expression assays to determine whether the patient is likely to respond to agents including PD-L1 axis binding antagonists (e.g., PD-L1 binding antagonists (e.g., anti-PD-L1 antibodies, such as Treatment with zizumab (MPDL3280A)) or a PD-1 binding antagonist (eg, anti-PD-1 antibody)) resulted in a response. To determine this possibility, physicians can assay for genes CST7, NK...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The compositions and methods described herein can be used, for example, to determine the propensity of a patient to benefit from treatment with a PD-L1 axis binding antagonist and to treat such patients accordingly. Using the compositions and methods of the disclosure, a patient, such as a human cancer patient, may be determined to be likely to benefit from treatment with a PD-L1 axis binding antagonist if the patient exhibits an elevated pre-treatment expression level of one or more of CST7, NKG7, GZMH, MT-ND4, HLA-H, CCL5, CD8A, CMC1, CD8B, HCST, MT-CYB, MT-ND4L, KLRG1, MT-CO2, MT-ATP6, PLEK, CTSW, HLA-C, LYAR, LITAF, GZMB, KLRD1, FGFBP2, KLRC4-KLRK1, KLRK1, B2M, GZMA, ID2, CX3CR1, PRSS23, GNLY, PRF1, and PATL2. Exemplary PD-L1 axis binding antagonists that may be used in conjunction with the compositions and methods of the disclosure are PD-L1 binding antagonists, such as anti-PD-L1 antibodies and antigen-binding fragments thereof, including atezolizumab, as well as PD-1 binding antagonists, such as anti-PD-1 antibodies and antigen-binding fragments thereof.

Description

[0001] sequence listing [0002] This application contains a Sequence Listing, which has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy was created on November 27, 2019, named 50474-188WO3_Sequence_Listing_11.27.19_ST25, and was 195,457 bytes in size. technical field [0003] The present invention relates to diagnostic and therapeutic methods for the treatment of cancer using PD-L1 axis binding antagonists. Related assays and kits are also provided. Background technique [0004] Cancer remains one of the deadliest threats to human health. In the United States, cancer strikes nearly 1.3 million new patients each year and is the second leading cause of death after heart disease, accounting for about a quarter of all deaths. In addition, it is predicted that cancer may overtake cardiovascular disease as the number one cause of death within 5 years. Solid tumors are the leading cause of these deaths. [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/30C12N5/0783A61P35/00
CPCC07K16/30C07K2319/33C07K2319/00A61P35/00C12N5/0636A61K35/17A61K39/3955G01N33/505C07K16/2827C07K2317/24C07K2317/76A61K2039/505A61K2039/507C07K16/22C12N2510/00A61K39/395A61K2300/00C07K16/2809A61K31/337C12Q1/6886C07K2319/30C12Q2600/158A61K45/06C07K14/7051C07K16/2818C12N5/0638C12Q2600/106
Inventor T·D·吴J·L·格罗根
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com